Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal CancerMarc Peeters, Jennifer Gansert, Timothy Price et al.|Journal of Clinical Oncology|2010Cited by 1k
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Andrea Cercek, Salvatore Siena et al.|The Lancet Oncology|2023Cited by 244
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancerMarc Peeters, R. Sidhu, Timothy Price et al.|Annals of Oncology|2013Cited by 220
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studiesNele Boeckx, Marc Peeters, Reija Koukakis et al.|Annals of Oncology|2017Cited by 219
Entrectinib: a potent new TRK, ROS1, and ALK inhibitorChristian Rolfo, Luis E. Raez, Rossana Ruiz et al.|Expert Opinion on Investigational Drugs|2015Cited by 153